Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co-Mutant Tumors.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) - 1 Jul 2026

Li Luo, Li Bolin, Hao Yanan, Pang Bo, Li Pan, Li Chunli, Tang Yu

Abstract excerpt

KRAS and TP53 co-mutations are frequently associated with highly aggressive, therapy-resistant cancers with limited treatment options. In this study, we have developed Autophagy-Targeting Chimera-T-cell Engager (AUTACE), a bifunctional nanoplatform composed of T-cell receptor-engineered T (TCR-T) cell-derived nanovesicles that display anti-CD3 antibodies and encapsulate perfluoropentane (PFP) together with KPY,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CCL5 gene

Share to MIA gene

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41944287
DOI: 10.1002/advs.202518455
PMCID: PMC13334621

Genes

KRAS
TP53
CCL5
MIA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co-Mutant Tumors.PMID 41944287Read ↗

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.Semantic proximity Read ↗

Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read ↗

Precision Nanotherapy for p53-Mutant Cancer Using Modular Triple-LNP DeliverySemantic proximity Read ↗

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read ↗

Reprogramming the Tolerogenic Immune Response Against Pancreatic Cancer Metastases by Lipid Nanoparticles Delivering a STING Agonist Plus Mutant KRAS mRNA.Semantic proximity Read ↗

Cancer Selective Target Degradation by Folate-Caged PROTACsSemantic proximity Read ↗

An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer.Semantic proximity Read ↗

Exploring the theranostic potential of carbon dots/Fe3 O4 superparticles for tumor-associated macrophage targeting and repolarization in colorectal cancer therapy via JAK/STAT and ERK/MAPK pathwaysSemantic proximity Read ↗

Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers.Semantic proximity Read ↗

Innovative Therapies for Oncogenic KRAS Mutations: Precision Strategies with PROTACs in Cancer Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.